Semaglutide Syringe Dosage: A Full Conversion Chart for Every Compounded Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited

Key Takeaways

• Compounded semaglutide is drawn from a multi-dose vial with a U-100 insulin syringe, not delivered through a pre-filled pen.
• The number of units to draw depends on two variables: your prescribed milligram dose and the concentration of your specific vial. Both must be confirmed before each injection.
• The standard titration schedule for semaglutide goes 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg per week, with at least 4 weeks at each step.
• A 0.3 mL or 0.5 mL U-100 insulin syringe with a 31-gauge, 5/16-inch needle is the standard for compounded GLP-1 dosing in 2026.
• Drawing the correct unit count is the single most error-prone step in compounded semaglutide therapy. A 30-second label check before each injection prevents most dosing mistakes.

Direct answer (40-60 words)

Semaglutide syringe dosage on a U-100 insulin syringe depends on your vial's concentration. At 2.5 mg/mL, the standard titration is 10 units (0.25 mg), 20 units (0.5 mg), 40 units (1.0 mg), 68 units (1.7 mg), and 96 units (2.4 mg) per week. Always confirm the concentration on your specific vial.

Table of contents

1. The 30-second answer
2. The standard semaglutide titration schedule
3. Syringe dosage chart at 2.5 mg/mL (most common)
4. Syringe dosage chart at every other common concentration
5. How to find your concentration on the vial label
6. Picking the right insulin syringe size
7. Step-by-step: drawing the correct semaglutide dose
8. Common syringe dosing errors and how to avoid them
9. When to call your prescriber about dosing
10. FAQ
11. Sources

The standard semaglutide titration schedule

The titration schedule used in the STEP trials (semaglutide for chronic weight management) and adapted by most U.S. prescribers in 2026 follows a five-step pattern (Wilding et al., NEJM 2021):

Some patients hold at lower doses (0.5 mg or 1.0 mg) if they are tolerating side effects poorly or seeing adequate progress at the lower dose. Some hold at 1.7 mg if 2.4 mg causes intolerable nausea. Titration is a clinical decision made between patient and prescriber, not a fixed schedule.

For the type 2 diabetes indication, the maximum dose is typically 2.0 mg per week (the Ozempic ceiling), while for chronic weight management it is 2.4 mg per week (the Wegovy ceiling). Compounded semaglutide is dosed by the prescriber and may follow either schedule.

The titration is the same regardless of whether you are using brand-name pens or compounded vials. What changes with compounded medication is how you measure the dose: instead of a pre-set pen click, you draw a specific number of units into a syringe.

Syringe dosage chart at 2.5 mg/mL (most common)

At 2.5 mg/mL, the most common concentration for compounded semaglutide in 2026:

A useful rule of thumb at 2.5 mg/mL: every 4 units delivers 0.1 mg of semaglutide. So 8 units = 0.2 mg, 12 units = 0.3 mg, and so on. This is the cleanest math of any common concentration, which is why most compounding pharmacies default to 2.5 mg/mL.

The 96-unit draw at the 2.4 mg dose exceeds the capacity of a 0.5 mL barrel (50 units). Patients on the 2.4 mg dose at 2.5 mg/mL need a 1 mL barrel U-100 syringe.

Syringe dosage chart at every other common concentration

A few practical observations from this chart:

• At 1 mg/mL, doses above 1.0 mg become difficult because they exceed standard insulin syringe capacities. Most pharmacies do not use 1 mg/mL for patients who will titrate above 1.0 mg.
• At 5 mg/mL, the 0.25 mg starter dose is only 5 units, which is at the lower limit of accurate readability on a 0.3 mL syringe. Many pharmacies switch concentrations between starter and maintenance phases.
• At 10 mg/mL, the 0.25 mg starter dose is 2.5 units, which is below the readable threshold for most patients. This concentration is reserved for patients on higher maintenance doses.

The right concentration is the one that places your prescribed dose in a unit range you can read accurately, typically 10 to 80 units.

How to find your concentration on the vial label

The concentration is printed on the vial in one of two formats:

• "Semaglutide 2.5 mg/mL" (direct concentration)
• "Semaglutide 5 mg / 2 mL Multi-Dose Vial" (calculate: 5 ÷ 2 = 2.5 mg/mL)

If your vial only shows total milligrams without a volume, the concentration appears in the dispensing instructions, the patient handout that came in the box, or the prescription label on the outer packaging.

Three places to look if the vial label is unclear:

1. The outer packaging. Pharmacies often print the full prescription details on the box even if the vial label is minimal.
2. The paper insert. Compounding pharmacies usually include a printed instruction sheet with the concentration in larger type.
3. The patient portal. Telehealth platforms typically post the dispensed prescription details in the patient's account.

If you cannot find the concentration in any of those places, call the pharmacy before drawing a dose. Two pharmacies can dispense identical-looking 10 mg vials at different concentrations. Guessing wrong leads to either a half dose or a double dose, both of which are clinically meaningful.

Picking the right insulin syringe size

U-100 insulin syringes come in three common barrel sizes:

The 0.3 mL barrel is the best choice for early titration (doses under 30 units) because the half-unit markings allow for finer precision at small volumes. The 1 mL barrel is necessary for the 2.4 mg dose at 2.5 mg/mL (96 units) but harder to read accurately at small volumes.

Needle gauge: 31-gauge is standard for subcutaneous GLP-1 injection. Higher numbers indicate thinner needles. Some patients prefer 32-gauge (slightly thinner) for less injection-site discomfort.

Needle length: 5/16 inch (8 mm) or 3/16 inch (5 mm) is appropriate for subcutaneous injection. The 5/16-inch needle is the most common.

The full set you need for each injection: a single U-100 insulin syringe with attached needle, two alcohol swabs, and access to a sharps container. Most compounding pharmacies include syringes with the medication shipment.

Step-by-step: drawing the correct semaglutide dose

The protocol below assumes a 2.5 mg/mL multi-dose vial and a target dose of 0.5 mg (20 units).

1. Wash your hands with soap and water for 20 seconds.
2. Inspect the vial. Compounded semaglutide should be clear and colorless to faint straw-yellow, or red/pink if your formulation includes vitamin B12. Do not use a vial that is cloudy, has visible particles, or has separated into layers.
3. Wipe the vial's rubber stopper with an alcohol swab and let it air-dry.
4. Pull the syringe plunger back to draw 20 units of air.
5. Insert the needle through the rubber stopper and push the air into the vial. (This equalizes pressure for an easier draw.)
6. Invert the vial with the needle still inserted. Pull the plunger back to draw 20 units of liquid.
7. Look for air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or flick the syringe sharply to dislodge bubbles, then push them back into the vial.
8. Confirm 20 units in the syringe by holding it at eye level. The plunger's leading edge (not the tail) should sit on the 20-unit line.
9. Remove the needle from the vial. Do not recap.
10. Choose an injection site. Subcutaneous sites include the abdomen (avoid 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly.
11. Wipe the injection site with the second alcohol swab. Let it air-dry.
12. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until the syringe is empty.
13. Withdraw the needle and apply gentle pressure with a clean tissue if there is any bleeding (rare).
14. Dispose of the syringe in a sharps container.

The whole process takes about 90 seconds once you are practiced. For a more detailed walkthrough on injection technique, see our subcutaneous injection guide.

Common syringe dosing errors and how to avoid them

The 2024 FDA Adverse Event Reporting System (FAERS) data on compounded GLP-1 dosing errors identified five recurring mistakes (FDA, 2024).

Error 1: Drawing the wrong unit count due to syringe-marking confusion. A 0.3 mL syringe has half-unit markings; a 0.5 mL syringe has full-unit markings. Patients counting "20 marks past zero" on a 0.3 mL syringe actually draw 10 units. Always read the printed numbers, not just count marks.

Error 2: Using the wrong concentration math after switching pharmacies. Pharmacy A uses 2.5 mg/mL. Pharmacy B uses 5 mg/mL. The same "20 units" delivers double the dose at Pharmacy B's concentration. Always re-check the concentration label when you receive a new vial.

Error 3: Confusing milliliters with milligrams. The vial label says "0.5 mg" and the patient draws 0.5 mL by mistake (50 units of liquid at 2.5 mg/mL would be 1.25 mg, not 0.5 mg). Write the unit count on the box once and refer to it before every injection.

Error 4: Drawing a stale dose. A vial that has been open for 28+ days may have lost potency. Compounded semaglutide is typically stable for 28 to 56 days after first puncture, depending on the pharmacy's beyond-use date (BUD) standards (USP <797>, 2023). Discard expired vials.

Error 5: Using a U-500 syringe instead of a U-100 syringe. U-500 syringes have 5x the marking value of U-100 syringes. Drawing "20 units" on a U-500 syringe delivers 100 units of liquid, which is 5 times the intended dose. Confirm "U-100" is printed on the syringe barrel before drawing.

A 2024 study (Patel et al., Annals of Pharmacotherapy 2024) found that 7.2% of patients self-administering compounded GLP-1 medications reported at least one suspected dosing error in the first 90 days of therapy. Most were over-doses, which is why titration-related side effects are higher in compounded patients than in pen-using patients.

When to call your prescriber about dosing

Call your prescriber within 24 hours if:

• You injected more than your prescribed dose by a margin large enough to matter (e.g., 40 units instead of 20 units, or any dose that is 50% higher than prescribed).
• You experience persistent vomiting (more than 12 hours), severe abdominal pain that does not resolve, signs of dehydration (dark urine, dizziness, confusion), or symptoms suggesting pancreatitis.
• You see signs of an allergic reaction (hives, swelling of the face or lips, difficulty breathing).
• Your vial looks visibly different from previous fills (cloudy, particulate, dramatic color change) and the pharmacy did not communicate a formulation update.

Most small dosing errors (1 to 3 units off the target) cause no clinical issue. Semaglutide's therapeutic window is wide enough that minor draw inaccuracies are typically irrelevant. The errors that warrant a call are the substantial ones (a 2x dose, a wrong-concentration draw, or a draw from a degraded vial).

For a deeper read on storage, shelf life, and signs of degradation, see our compounded semaglutide storage guide.

FAQ

What size syringe do I use for compounded semaglutide? A U-100 insulin syringe with a 31-gauge, 5/16-inch needle is standard. Choose 0.3 mL barrel for doses under 30 units, 0.5 mL barrel for 25 to 50 units, and 1 mL barrel for over 50 units.

How many units of semaglutide is 0.25 mg? At the most common concentration (2.5 mg/mL), 0.25 mg equals 10 units. At 5 mg/mL it is 5 units. At 1 mg/mL it is 25 units. Always confirm the concentration on your specific vial.

How many units of semaglutide is 0.5 mg? At 2.5 mg/mL, 0.5 mg equals 20 units. At 5 mg/mL it is 10 units. At 1 mg/mL it is 50 units. The concentration determines the math.

How many units of semaglutide is 1 mg? At 2.5 mg/mL, 1.0 mg equals 40 units. At 5 mg/mL it is 20 units. At 1 mg/mL it is 100 units. At 10 mg/mL it is 10 units.

How many units of semaglutide is 2.4 mg? At 2.5 mg/mL, 2.4 mg equals 96 units, which requires a 1 mL barrel U-100 syringe. At 5 mg/mL it is 48 units. At 10 mg/mL it is 24 units.

Can I use a regular hypodermic syringe instead of an insulin syringe? Insulin syringes are preferred because their unit markings are calibrated for the small volumes GLP-1 dosing requires. A regular tuberculin syringe with mL markings can work but introduces more reading error at small volumes.

How long is a compounded semaglutide vial good for after first puncture? Most U.S. compounding pharmacies use a 28 to 56 day beyond-use date (BUD) for multi-dose semaglutide vials, depending on whether the formulation contains a preservative. Check your specific vial's BUD on the label.

What if my dose falls between unit markings? At small doses, rounding by 0.5 to 1 unit is usually clinically irrelevant. Do not round by more than 1 unit without confirming with your prescriber. Rounding down is generally safer if you are unsure.

Should I draw the dose right before injecting or in advance? Draw immediately before injecting. Pre-drawn syringes are not generally recommended unless you are following specific instructions from your pharmacy or prescriber.

What if I see air bubbles in my drawn syringe? Push the liquid back into the vial and re-draw, or flick the syringe sharply to dislodge bubbles, then push them out. Small bubbles in subcutaneous injections are typically not dangerous (unlike intravenous), but they reduce the actual medication delivered.

Can I reuse an insulin syringe? No. Insulin syringes are single-use. Reusing them dulls the needle, increases injection-site pain, and risks contamination. Dispose of each syringe in a sharps container immediately after use.

What if I miss my weekly semaglutide dose? If less than 5 days have passed since the missed dose, take it as soon as you remember and continue on your regular schedule. If 5 or more days have passed, skip the missed dose and resume on the next scheduled day. Do not double up.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
3. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight (STEP 8). JAMA. 2022;327(2):138-150.
4. U.S. Pharmacopeia. General Chapter <797> Pharmaceutical Compounding, Sterile Preparations. USP, 2023.
5. U.S. Food and Drug Administration. FDA Adverse Event Reporting System Public Dashboard. FDA, 2024.
6. Patel R, Singh A, Goldman S, et al. Self-reported dosing errors with compounded GLP-1 receptor agonists. Annals of Pharmacotherapy. 2024;58(6):412-420.
7. International Organization for Standardization. ISO 8537: Sterile single-use syringes, with or without needle, for insulin. ISO, 2016.
8. American Diabetes Association. Standards of Care in Diabetes. ADA, 2024.
9. Novo Nordisk. Wegovy and Ozempic prescribing information. Novo Nordisk, 2024.
10. National Institutes of Health Office of Dietary Supplements. Vitamin B12 fact sheet. NIH, 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.